CADL Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Candel Therapeutics's net margin of -49.65%. Candel Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Candel Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 203.47%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that Candel Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Candel Therapeutics is more attractive than NovaBay Pharmaceuticals.

Candel Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Candel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Candel Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Candel Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Candel Therapeutics's net income of $7.4M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Candel Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics is 2,124.14x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix has a net margin of -- compared to Candel Therapeutics's net margin of -598.74%. Candel Therapeutics's return on equity of -- beat Ocular Therapeutix's return on equity of -56.05%.

Candel Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 203.47%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.92 which suggests that it could grow by 57.44%. Given that Candel Therapeutics has higher upside potential than Ocular Therapeutix, analysts believe Candel Therapeutics is more attractive than Ocular Therapeutix.

Candel Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.431, suggesting its more volatile than the S&P 500 by 43.081%.

Candel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Candel Therapeutics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

Candel Therapeutics quarterly revenues are --, which are smaller than Ocular Therapeutix quarterly revenues of $10.7M. Candel Therapeutics's net income of $7.4M is higher than Ocular Therapeutix's net income of -$64.1M. Notably, Candel Therapeutics's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics is 2,124.14x versus 31.97x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of -- compared to Candel Therapeutics's net margin of -271.3%. Candel Therapeutics's return on equity of -- beat Spero Therapeutics's return on equity of -108.26%.

Candel Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 203.47%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 101.61%. Given that Candel Therapeutics has higher upside potential than Spero Therapeutics, analysts believe Candel Therapeutics is more attractive than Spero Therapeutics.

Candel Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spero Therapeutics has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.062%.

Candel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Candel Therapeutics pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Candel Therapeutics quarterly revenues are --, which are smaller than Spero Therapeutics quarterly revenues of $5.1M. Candel Therapeutics's net income of $7.4M is higher than Spero Therapeutics's net income of -$13.9M. Notably, Candel Therapeutics's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics is 2,124.14x versus 4.78x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Candel Therapeutics's net margin of --. Candel Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

Candel Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 203.47%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1367.51%. Given that Theriva Biologics has higher upside potential than Candel Therapeutics, analysts believe Theriva Biologics is more attractive than Candel Therapeutics.

Candel Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Candel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Candel Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Candel Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Candel Therapeutics's net income of $7.4M is higher than Theriva Biologics's net income of -$4.3M. Notably, Candel Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics is 2,124.14x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.